A Phase 3 interventional study of Fluticasone furoate in Rhinitis, sponsored by GlaxoSmithKline. Completed at 6 sites in Japan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rhinitis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis · GlaxoSmithKline.
Among the 25 studies in Rhinitis by GlaxoSmithKline, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 3, and was the 16th registered.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
Browse Rhinitis studies →None of the 25 studies in Rhinitis by GlaxoSmithKline is open now. The open studies under Rhinitis, anywhere →
Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 80 across 187 interventional studies indexed under Rhinitis.
Median enrollment 56 across the 21 interventional studies, 2,622 across the 4 observational. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Rhinitis by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will be evaluated. And secondarily, efficacy and systemic exposure of GW685698X (55 µg/day, q.d.) nasal spray over a period of 12 weeks in Japanese paediatric subjects ages 2 to \< 15 years with perennial allergic rhinitis will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Anti-IgE (Within 6 months prior to Visit 1), medications or Systemic corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to Visit 1
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GW685698X 55mcg/day
Drug: Fluticasone furoate
55 mcg/day, intranasal, 12 weeks
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an other important medical event, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.
Time frame: From the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks)
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophil Count at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline. Basophils, eosinophils, lymphocytes, monocytes, and total neutrophil counts are measured as the percentage of cells in white blood cells.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Hemoglobin at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Red Blood Cell (RBC) Count at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Hematocrit at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Albumin and Total Protein at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyltransferase (GGT) at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Direct Bilirubin, Total Bilirubin, and Creatinine at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Change From Baseline in Calcium, Chloride, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 4 and Week 12/Early Withdrawal
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
Time frame: Baseline, Week 4, and Week 12/Early Withdrawal
Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Percent Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Change From Baseline (BL) in Daily Variation of the 3 Total Nasal Symptom Score (3TNSS)
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The BL value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from BL was calculated as the mean score for the entire treatment period minus the score at BL. Only those participants available at the indicated time points were assessed.
Time frame: Baseline, Day 1 to Day 84
Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Percent Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Percent Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Change From Baseline in Sneezing, Rhinorrhea, Nasal Congestion, and Nasal Itching Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Change From Baseline in Eye Itching, Tearing, and Redness Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Three individual symptoms (eye itching, tearing, and redness) were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline through the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge)
Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).
Time frame: Baseline, Week 4, Week 8, and Week 12/early withdrawal
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
Time frame: Week 12/early withdrawal
Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
The participant's parent/guardian who signed the ICF or the participant himself/herself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
Time frame: Week 12/early withdrawal
Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=2 to <6 Years
Pharmacokinetic (PK) samples were collected to analyze the plasma concentration of GW685698X.
Time frame: Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)
Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=6 to <15 Years
PK samples were collected to analyze the plasma concentration of GW685698X.
Time frame: Between 0.5 to 2 hours after final dosing at Week 12 (Visit 5)
| Milestone | GW685698X 55 μg QD |
|---|---|
| Started | 61 |
| Completed | 59 |
| Not completed | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an other important medical event, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occurring at a frequency threshold \>=5%) and SAEs.
| participants | GW685698X 55 μg QD |
|---|---|
| Any AE | 41 |
| Any SAE | 0 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline. Basophils, eosinophils, lymphocytes, monocytes, and total neutrophil counts are measured as the percentage of cells in white blood cells.
| Percentage of cells | GW685698X 55 μg QD |
|---|---|
| Basophils, Week 4, n=60 | -0.08 ± 0.353 |
| Basophils, Week 12/early withdrawal, n=61 | -0.12 ± 0.356 |
| Eosinophils, Week 4, n=60 | -0.29 ± 2.538 |
| Eosinophils, Week 12/early withdrawal, n=61 | -1.38 ± 2.991 |
| Lymphocytes, Week 4, n=60 | -1.22 ± 6.863 |
| Lymphocytes, Week 12/early withdrawal, n=61 | -1.77 ± 8.181 |
| Monocytes, Week 4, n=60 | 0.24 ± 1.604 |
| Monocytes, Week 12/early withdrawal, n=61 | 0.26 ± 1.714 |
| Total Neutrophils, Week 4, n=60 | 1.36 ± 8.355 |
| Total Neutrophils, Week 12/early withdrawal, n=61 | 3.02 ± 9.684 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| Grams per liter (grams/L) | GW685698X 55 μg QD |
|---|---|
| Hemoglobin, Week 4, n=60 | -1.9 ± 7.34 |
| Hemoglobin, Week 12/early withdrawal, n=61 | 0.1 ± 6.09 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| giga (10^9) cells (GI)/L | GW685698X 55 μg QD |
|---|---|
| Platelet count, Week 4, n=60 | -0.4 ± 54.95 |
| Platelet count, Week 12/early withdrawal, n=61 | -2.9 ± 56.26 |
| WBC count, Week 4, n=60 | -0.45 ± 1.860 |
| WBC count, Week 12/early withdrawal, n=61 | -0.00 ± 2.092 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| tera (10^12) cells (TI)/L | GW685698X 55 μg QD |
|---|---|
| RBC count, Week 4, n=60 | -0.081 ± 0.2386 |
| RBC count, Week 12/early withdrawal, n=61 | -0.039 ± 0.2080 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| Proportion of RBCs in blood | GW685698X 55 μg QD |
|---|---|
| Hematocrit, Week 4, n=60 | -0.0061 ± 0.01965 |
| Hematocrit, Week 12/early withdrawal, n=61 | -0.0062 ± 0.01824 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| grams/L | GW685698X 55 μg QD |
|---|---|
| Albumin, Week 4, n=60 | -1.4 ± 2.05 |
| Albumin, Week 12/early withdrawal, n=61 | -0.8 ± 1.93 |
| Total protein, Week 4, n=60 | -1.8 ± 3.41 |
| Total protein, Week 12/early withdrawal, n=61 | -0.9 ± 3.36 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| International units (IU)/L | GW685698X 55 μg QD |
|---|---|
| ALP, Week 4, n=60 | -49.9 ± 89.43 |
| ALP, Week 12/early withdrawal, n=61 | 88.5 ± 586.10 |
| ALT, Week 4, n=60 | 0.7 ± 4.19 |
| ALT, Week 12/early withdrawal, n=61 | 0.4 ± 4.72 |
| AST, Week 4, n=60 | -0.3 ± 3.45 |
| AST, Week 12/early withdrawal, n=61 | 0.2 ± 3.39 |
| GGT, Week 4, n=60 | -0.1 ± 1.63 |
| GGT, Week 12/early withdrawal, n=61 | 0.1 ± 1.95 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| Micromoles (μmol)/L | GW685698X 55 μg QD |
|---|---|
| Direct bilirubin, Week 4, n=60 | 0.114 ± 0.9889 |
| Direct bilirubin, Week 12/early withdrawal, n=61 | -0.028 ± 0.8545 |
| Total bilirubin, Week 4, n=60 | 0.370 ± 2.2504 |
| Total bilirubin, Week 12/early withdrawal, n=61 | -0.533 ± 2.2844 |
| Creatinine, Week 4, n=60 | -1.6649 ± 5.21356 |
| Creatinine, Week 12/early withdrawal, n=61 | -0.5797 ± 5.63473 |
Change from Baseline was calculated as the value at the post-Baseline time points minus the value at Baseline.
| Millimoles (mmol)/L | GW685698X 55 μg QD |
|---|---|
| Calcium, Week 4, n=60 | -0.0541 ± 0.09085 |
| Calcium, Week 12/early withdrawal, n=61 | -0.0372 ± 0.07480 |
| Chloride, Week 4, n=60 | 1.3 ± 2.27 |
| Chloride, Week 12/early withdrawal, n=61 | 1.1 ± 2.04 |
| Potassium, Week 4, n=60 | -0.13 ± 0.378 |
| Potassium, Week 12/early withdrawal, n=61 | -0.06 ± 0.380 |
| Sodium, Week 4, n=60 | -0.4 ± 1.70 |
| Sodium, Week 12/early withdrawal, n=61 | -1.2 ± 1.58 |
| Urea/BUN, Week 4, n=60 | -0.4998 ± 1.12504 |
| Urea/BUN, Week 12/early withdrawal, n=61 | -0.0954 ± 1.18765 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the mean score for the entire treatment period minus the score at Baseline.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=61 | -2.2 ± 1.65 |
| Week 1 to 2, n=61 | -1.6 ± 1.58 |
| Week 3 to 4, n=61 | -2.5 ± 1.84 |
| Week 7 to 8, n=60 | -2.4 ± 1.86 |
| Week 11 to 12, n=60 | -2.0 ± 2.07 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
| Percent change | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=61 | -46.9 ± 33.25 |
| Week 1 to 2, n=61 | -31.6 ± 36.36 |
| Week 3 to 4, n=61 | -53.2 ± 36.81 |
| Week 7 to 8, n=60 | -50.9 ± 38.00 |
| Week 11 to 12, n=60 | -40.7 ± 41.58 |
The 3TNSS is the sum of the 3 individual symptom scores for sneezing, rhinorrhea, and nasal congestion. Each symptom is scored on a scale from 0 to 3; the range of sums for the 3TNSS is 0 to 9. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the informed consent form (ICF) or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The BL value is defined as the average 3TNSS over the last 4 consecutive days prior to Visit 2 (start of the treatment period). For the entire assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from BL was calculated as the mean score for the entire treatment period minus the score at BL. Only those participants available at the indicated time points were assessed.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Day 1, n=61 | -0.5 ± 1.81 |
| Day 2, n=61 | -0.8 ± 1.90 |
| Day 3, n=61 | -0.9 ± 1.64 |
| Day 4, n=61 | -1.3 ± 1.76 |
| Day 5, n=61 | -1.4 ± 1.75 |
| Day 6, n=61 | -1.3 ± 1.76 |
| Day 7, n=61 | -1.6 ± 1.83 |
| Day 8, n=61 | -1.9 ± 1.94 |
| Day 9, n=61 | -1.9 ± 2.12 |
| Day 10, n=61 | -2.0 ± 1.90 |
| Day 11, n=61 | -1.8 ± 2.18 |
| Day 12, n=61 | -1.9 ± 1.98 |
| Day 13, n=61 | -2.3 ± 2.12 |
| Day 14, n=61 | -2.2 ± 2.21 |
| Day 15, n=61 | -2.5 ± 2.12 |
| Day 16, n=61 | -2.3 ± 2.05 |
| Day 17, n=61 | -2.4 ± 2.01 |
| Day 18, n=61 | -2.5 ± 1.96 |
| Day 19, n=61 | -2.6 ± 2.01 |
| Day 20, n=61 | -2.7 ± 2.00 |
| Day 21, n=61 | -2.5 ± 2.08 |
| Day 22, n=61 | -2.6 ± 2.03 |
| Day 23, n=61 | -2.4 ± 2.04 |
| Day 24, n=61 | -2.4 ± 2.13 |
| Day 25, n=61 | -2.5 ± 1.91 |
| Day 26, n=61 | -2.5 ± 2.08 |
| Day 27, n=61 | -2.5 ± 1.97 |
| Day 28, n=61 | -2.4 ± 1.99 |
| Day 29, n=60 | -2.4 ± 1.81 |
| Day 30, n=60 | -2.5 ± 1.79 |
| Day 31, n=60 | -2.6 ± 1.90 |
| Day 32, n=60 | -2.4 ± 2.16 |
| Day 33, n=60 | -2.5 ± 1.99 |
| Day 34, n=60 | -2.4 ± 2.30 |
| Day 35, n=60 | -2.4 ± 2.43 |
| Day 36, n=60 | -2.2 ± 2.21 |
| Day 37, n=60 | -2.4 ± 2.23 |
| Day 38, n=60 | -2.4 ± 2.41 |
| Day 39, n=60 | -2.2 ± 2.30 |
| Day 40, n=60 | -2.2 ± 2.17 |
| Day 41, n=60 | -2.3 ± 1.85 |
| Day 42, n=60 | -2.6 ± 1.80 |
| Day 43, n=60 | -2.4 ± 2.20 |
| Day 44, n=60 | -2.5 ± 2.16 |
| Day 45, n=60 | -2.2 ± 2.24 |
| Day 46, n=60 | -2.5 ± 1.89 |
| Day 47, n=60 | -2.5 ± 2.07 |
| Day 48, n=60 | -2.4 ± 2.27 |
| Day 49, n=60 | -2.4 ± 2.15 |
| Day 50, n=60 | -2.4 ± 2.33 |
| Day 51, n=60 | -2.4 ± 2.34 |
| Day 52, n=60 | -2.4 ± 1.99 |
| Day 53, n=60 | -2.5 ± 1.90 |
| Day 54, n=60 | -2.2 ± 1.98 |
| Day 55, n=60 | -2.2 ± 2.11 |
| Day 56, n=60 | -2.3 ± 2.11 |
| Day 57, n=60 | -2.4 ± 1.94 |
| Day 58, n=60 | -2.4 ± 1.98 |
| Day 59, n=60 | -2.6 ± 2.09 |
| Day 60, n=60 | -2.8 ± 1.75 |
| Day 61, n=60 | -2.5 ± 1.78 |
| Day 62, n=60 | -2.6 ± 1.65 |
| Day 63, n=60 | -2.7 ± 1.77 |
| Day 64, n=60 | -2.6 ± 1.96 |
| Day 65, n=60 | -2.5 ± 2.07 |
| Day 66, n=60 | -2.2 ± 2.24 |
| Day 67, n=60 | -2.4 ± 2.10 |
| Day 68, n=60 | -2.3 ± 2.23 |
| Day 69, n=60 | -2.4 ± 1.96 |
| Day 70, n=60 | -2.5 ± 1.79 |
| Day 71, n=60 | -2.4 ± 1.99 |
| Day 72, n=60 | -2.1 ± 1.97 |
| Day 73, n=60 | -2.0 ± 2.17 |
| Day 74, n=59 | -1.6 ± 2.37 |
| Day 75, n=59 | -1.8 ± 2.34 |
| Day 76, n=59 | -1.8 ± 2.56 |
| Day 77, n=59 | -2.1 ± 2.59 |
| Day 78, n=59 | -2.1 ± 2.49 |
| Day 79, n=59 | -1.9 ± 2.35 |
| Day 80, n=59 | -1.8 ± 2.15 |
| Day 81, n=50 | -1.9 ± 2.25 |
| Day 82, n=43 | -1.7 ± 2.45 |
| Day 83, n=39 | -1.2 ± 2.55 |
| Day 84, n=31 | -1.2 ± 2.55 |
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Scores on a scale | -2.6 ± 2.01 |
| Week 1 to 2 n=61 | -1.8 ± 1.93 |
| Week 3 to 4, n=61 | -2.9 ± 2.26 |
| Week 7 to 8, n=60 | -2.8 ± 2.26 |
| Week 11 to 12, n=60 | -2.3 ± 2.50 |
The 4TNSS is the sum of the 4 individual symptom scores for sneezing, rhinorrhea, nasal congestion, and nasal itching. Each symptom is scored on a scale from 0 to 3; the range of sums for the 4TNSS is 0 to 12. The symptoms were evaluated using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the 4TNSS in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
| Percent change | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=61 | -47.1 ± 34.06 |
| Week 1 to 2, n=61 | -31.3 ± 38.42 |
| Week 3 to 4, n=61 | -52.8 ± 38.62 |
| Week 7 to 8, n=60 | -51.3 ± 38.90 |
| Week 11 to 12, n=60 | -42.0 ± 41.95 |
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=61 | -0.2 ± 1.00 |
| Week 1 to 2, n=61 | -0.1 ± 0.88 |
| Week 3 to 4, n=61 | -0.1 ± 1.08 |
| Week 7 to 8, n=60 | -0.2 ± 1.20 |
| Week 11 to 12, n=60 | -0.3 ± 1.06 |
Symptoms of eye itching, tearing, and redness were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The TOSS is the sum of all three symtpom scores and ranges from 0 to 9. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Percent change from Baseline=(mean score at the post-Baseline assessment minus the score at Baseline) divided by the Baseline value \* 100.
| Percent change | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=36 | 7.1 ± 180.60 |
| Week 1 to 2, n=36 | 4.6 ± 138.41 |
| Week 3 to 4, n=36 | 17.5 ± 214.79 |
| Week 7 to 8, n=35 | 29.0 ± 251.46 |
| Week 11 to 12, n=35 | -22.5 ± 163.35 |
Four individual symptoms (sneezing, rhinorrhea, nasal congestion, and nasal itching) were scored on a scale from 0 to 3 using a scale of 0, 1, 2, or 3; a larger score indicates more severe symptoms. The participant's parent/guardian who signed the ICF or the participant themself scored nasal symptoms every day during the screening period and the treatment period. The Baseline value is defined as the average of the symptom scores in the last 4 consecutive days prior to Visit 2 (start of the treatment period). A mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Sneezing, Entire Treatment Period, n=61 | -0.7 ± 0.74 |
| Sneezing, Week 1 to 2, n=61 | -0.5 ± 0.67 |
| Sneezing, Week 3 to 4, n=61 | -0.8 ± 0.75 |
| Sneezing, Week 7 to 8, n=60 | -0.7 ± 0.81 |
| Sneezing, Week 11 to 12, n=60 | -0.6 ± 0.88 |
| Rhinorrhea, Entire Treatment Period, n=61 | -0.8 ± 0.65 |
| Rhinorrhea, Week 1 to 2, n=61 | -0.5 ± 0.62 |
| Rhinorrhea, Week 3 to 4, n=61 | -0.9 ± 0.76 |
| Rhinorrhea, Week 7 to 8, n=60 | -0.8 ± 0.73 |
| Rhinorrhea, Week 11 to 12, n=60 | -0.7 ± 0.85 |
| Nasal Congestion, Entire Treatment Period, n=61 | -0.8 ± 0.66 |
| Nasal Congestion, Week 1 to 2, n=61 | -0.5 ± 0.63 |
| Nasal Congestion, Week 3 to 4, n=61 | -0.9 ± 0.76 |
| Nasal Congestion, Week 7 to 8, n=60 | -0.8 ± 0.72 |
| Nasal Congestion, Week 11 to 12, n=60 | -0.7 ± 0.85 |
| Nasal Itching, Entire Treatment Period, n=61 | -0.4 ± 0.58 |
| Nasal Itching, Week 1 to 2, n=61 | -0.2 ± 0.55 |
| Nasal Itching, Week 3 to 4, n=61 | -0.4 ± 0.63 |
| Nasal Itching, Week 7 to 8, n=60 | -0.4 ± 0.67 |
| Nasal Itching, Week 11 to 12, n=60 | -0.3 ± 0.69 |
Three individual symptoms (eye itching, tearing, and redness) were scored by the participant's parent/guardian who signed the ICF or the participant themself using a scale of 0, 1, 2, or 3 (a larger score indicates more severe symptoms) and were recorded in the participant's diary. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period (12 weeks), Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Eye Itching, Entire Treatment Period, n=61 | -0.2 ± 0.57 |
| Eye Itching, Week 1 to 2, n=61 | -0.1 ± 0.53 |
| Eye Itching, Week 3 to 4, n=61 | -0.1 ± 0.61 |
| Eye Itching, Week 7 to 8, n=60 | -0.2 ± 0.68 |
| Eye Itching, Week 11 to 12, n=60 | -0.2 ± 0.59 |
| Tearing, Entire Treatment Period, n=61 | 0.0 ± 0.25 |
| Tearing, Week 1 to 2, n=61 | 0.0 ± 0.22 |
| Tearing, Week 3 to 4, n=61 | 0.0 ± 0.29 |
| Tearing, Week 7 to 8, n=60 | 0.0 ± 0.28 |
| Tearing, Week 11 to 12, n=60 | 0.0 ± 0.26 |
| Redness, Entire Treatment Period, n=61 | -0.1 ± 0.34 |
| Redness, Week 1 to 2, n=61 | -0.0 ± 0.32 |
| Redness, Week 3 to 4, n=61 | -0.0 ± 0.35 |
| Redness, Week 7 to 8, n=60 | -0.0 ± 0.43 |
| Redness, Week 11 to 12, n=60 | -0.1 ± 0.39 |
The participant's parent/guardian who signed the ICF or the participant themself scored the participant's troubles with daily life once daily using the following scale: 0, None; 1, Few troubles; 2, Intermediate between 3 and 1; or 3, Painful and complicating daily life. The mean of the Baseline period is defined as the mean score of 4 consecutive days prior to Visit 2 (start of the treatment period). The mean of each assessment period is defined as the mean score of the entire treatment period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12. For each assessment period, a mean score for each participant was calculated using available diary data from the assessment periods, taking the average of non-missing data during the period. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Scores on a scale | GW685698X 55 μg QD |
|---|---|
| Entire Treatment Period, n=61 | -0.5 ± 0.61 |
| Week 1 to 2, n=61 | -0.3 ± 0.52 |
| Week 3 to 4, n=61 | -0.5 ± 0.65 |
| Week 7 to 8, n=60 | -0.6 ± 0.72 |
| Week 11 to 12, n=60 | -0.4 ± 0.75 |
Rhinoscopy was assessed by the investigator by scoring swelling of inferior turbinate mucosa (SOITM) scored as 0 (none), 1 (possible to see center of the middle turbinate), 2 (between 3 and 1), or 3 (impossible to see middle turbinate); color of inferior turbinate mucosa (COITM) scored as 0 (normal), 1 (pink), 2 (red), or 3 (pale); quantity of nasal discharge (QTND) scored as 0 (none), 1 (small amount adhered), 2 (between 3 and 1), or 3 (filled); and quality of nasal discharge (QLND) scored as 0 (none), 1 (pyoid), 2 (viscous), or 3 (watery).
| participants | GW685698X 55 μg QD |
|---|---|
| SOITM, Baseline, Score 0, n=61 | 3 |
| SOITM, Baseline, Score 1, n=61 | 9 |
| SOITM, Baseline, Score 2, n=61 | 35 |
| SOITM, Baseline, Score 3, n=61 | 14 |
| SOITM, Week 4, Score 0, n=60 | 15 |
| SOITM, Week 4, Score 1, n=60 | 21 |
| SOITM, Week 4, Score 2, n=60 | 23 |
| SOITM, Week 4, Score 3, n=60 | 1 |
| SOITM, Week 8, Score 0, n=60 | 17 |
| SOITM, Week 8, Score 1, n=60 | 24 |
| SOITM, Week 8, Score 2, n=60 | 19 |
| SOITM, Week 8, Score 3, n=60 | 0 |
| SOITM, Week 12/early withdrawal, Score 0, n=61 | 21 |
| SOITM, Week 12/early withdrawal, Score 1, n=61 | 26 |
| SOITM, Week 12/early withdrawal, Score 2, n=61 | 13 |
| SOITM, Week 12/early withdrawal, Score 3, n=61 | 1 |
| COITM, Baseline, Score 0, n=61 | 0 |
| COITM, Baseline, Score 1, n=61 | 10 |
| COITM, Baseline, Score 2, n=61 | 23 |
| COITM, Baseline, Score 3, n=61 | 28 |
| COITM, Week 4, Score 0, n=60 | 10 |
| COITM, Week 4, Score 1, n=60 | 28 |
| COITM, Week 4, Score 2, n=60 | 13 |
| COITM, Week 4, Score 3, n=60 | 9 |
| COITM, Week 8, Score 0, n=60 | 12 |
| COITM, Week 8, Score 1, n=60 | 30 |
| COITM, Week 8, Score 2, n=60 | 11 |
| COITM, Week 8, Score 3, n=60 | 7 |
| COITM, Week 12/early withdrawal, Score 0, n=61 | 19 |
| COITM, Week 12/early withdrawal, Score 1, n=61 | 28 |
| COITM, Week 12/early withdrawal, Score 2, n=61 | 10 |
| COITM, Week 12/early withdrawal, Score 3, n=61 | 4 |
| QTND, Baseline, Score 0, n=61 | 4 |
| QTND, Baseline, Score 1, n=61 | 16 |
| QTND, Baseline, Score 2, n=61 | 33 |
| QTND, Baseline, Score 3, n=61 | 8 |
| QTND, Week 4, Score 0, n=60 | 30 |
| QTND, Week 4, Score 1, n=60 | 24 |
| QTND, Week 4, Score 2, n=60 | 5 |
| QTND, Week 4, Score 3, n=60 | 1 |
| QTND, Week 8, Score 0, n=60 | 29 |
| QTND, Week 8, Score 1, n=60 | 25 |
| QTND, Week 8, Score 2, n=60 | 4 |
| QTND, Week 8, Score 3, n=60 | 2 |
| QTND, Week 12/early withdrawal, Score 0, n=61 | 34 |
| QTND, Week 12/early withdrawal, Score 1, n=61 | 24 |
| QTND, Week 12/early withdrawal, Score 2, n=61 | 3 |
| QTND, Week 12/early withdrawal, Score 3, n=61 | 0 |
| QLND, Baseline, Score 0, n=61 | 4 |
| QLND, Baseline, Score 1, n=61 | 0 |
| QLND, Baseline, Score 2, n=61 | 14 |
| QLND, Baseline, Score 3, n=61 | 43 |
| QLND, Week 4, Score 0, n=60 | 30 |
| QLND, Week 4, Score 1, n=60 | 11 |
| QLND, Week 4, Score 2, n=60 | 4 |
| QLND, Week 4, Score 3, n=60 | 15 |
| QLND, Week 8, Score 0, n=60 | 30 |
| QLND, Week 8, Score 1, n=60 | 13 |
| QLND, Week 8, Score 2, n=60 | 5 |
| QLND, Week 8, Score 3, n=60 | 12 |
| QLND, Week 12/early withdrawal, Score 0, n=61 | 32 |
| QLND, Week 12/early withdrawal, Score 1, n=61 | 10 |
| QLND, Week 12/early withdrawal, Score 2, n=61 | 7 |
| QLND, Week 12/early withdrawal, Score 3, n=61 | 12 |
The investigator evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
| participants | GW685698X 55 μg QD |
|---|---|
| Significantly Improved | 25 |
| Moderately Improved | 28 |
| Mildly Improved | 3 |
| No Change | 5 |
| Mildly Worse | 0 |
| Moderately Worse | 0 |
| Significantly Worse | 0 |
The participant's parent/guardian who signed the ICF or the participant himself/herself evaluated the participant's overall response to therapy (defined as improvement in the symptoms of allergic rhinitis) compared with Visit 2 (start of the treatment period), using the following 7-point categorical scale: 1=significantly improved, 2=moderately improved, 3=mildly improved, 4=no change, 5=mildly worse, 6=moderately worse, and 7=significantly worse.
| participants | GW685698X 55 μg QD |
|---|---|
| Significantly Improved | 13 |
| Moderately Improved | 31 |
| Mildly Improved | 12 |
| No Change | 4 |
| Mildly Worse | 1 |
| Moderately Worse | 0 |
| Significantly Worse | 0 |
Pharmacokinetic (PK) samples were collected to analyze the plasma concentration of GW685698X.
| participants | GW685698X 55 μg QD |
|---|---|
| Not Quantifiable (<10 picograms/milliliter [pg/mL] | 17 |
| >=10 to <20 pg/mL | 2 |
| >=20 to <30 pg/mL | 0 |
| >=30 pg/mL | 0 |
PK samples were collected to analyze the plasma concentration of GW685698X.
| participants | GW685698X 55 μg QD |
|---|---|
| Not Quantifiable (<10 pg/mL) | 37 |
| >=10 to <20 pg/mL | 2 |
| >=20 to <30 pg/mL | 1 |
| >=30 pg/mL | 0 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment (Visit 2) until follow-up contact (Visit 6) (up to 13 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GW685698X 55 μg QD | — | 0/61 (0%) | 23/61 (37.7%) |
| Event | GW685698X 55 μg QD |
|---|---|
| NasopharyngitisInfections and infestations | 15/61 |
| Acute sinusitisInfections and infestations | 8/61 |
| Age, Continuous(Years) | GW685698X 55 μg QD |
|---|---|
| Mean | 8.0 ± 3.59 |
| Gender(Participants) | GW685698X 55 μg QD |
|---|---|
| Female | 19 |
| Male | 42 |
| Race/Ethnicity, Customized(participants) | GW685698X 55 μg QD |
|---|---|
| Asian - Japanese Heritage | 61 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate